INTRODUCTION
Glaucoma is a progressive optic neuropathy identified by characteristic optic disc, retinal nerve fiber layer (RNFL) and visual field damage and change that occur as a result of retinal ganglion cell damage and death. Detecting structural and functional change is one of the most challenging aspects of glaucoma management. [1] [2] [3] [4] Detecting progression requires detailed documentation of the appearance of the optic disc and visual field at each visit so that change over time can be identified. In the clinical setting, structural change is usually identified based on a thorough clinical examination, with a drawing or written description of the optic disc and retinal nerve fiber layer often augmented with subjective assessment of optic disc photographs to summarize the examination results. Automated perimetry provides objective documentation of visual function that can be used to compare visual fields over time.
Fortunately, objective tools to document structural and functional change have been improving. In addition to subjective assessment of the optic disc and RNFL by clinical examination or photograph review objective methods including confocal scanning laser ophthalmoscopy, scanning laser polarimetry and optical coherence tomography are available to provide documentation of the optic disc and RNFL with sophisticated statistical analyses for glaucoma management. In addition to standard automated perimetry, selective perimetric techniques such as short wavelength automated perimetry (SWAP) and frequency doubling perimetry are now available to detect and monitor glaucomatous visual field changes.
Naturally, the ability to detect structural and functional change in glaucoma will vary depending on which structural and functional techniques are used. Other factors, including how glaucomatous change is defined, and the severity of disease will also affect the ability to detect glaucomatous change. This brief overview will summarize what we know about the temporal relationship between structural and functional change in glaucoma and how this information can be used in clinical practice. This review will focus on the limited number of welldesigned longitudinal studies (randomized clinical trials and observational cohort studies) that measured structural and functional change over time in order to answer the question: Is structural change usually detectable before functional change in glaucoma? This review will also briefly highlight study design issues that may explain differences in results across studies so that clinicians can better apply the information to their specific clinical populations.
RANDOMIZED CLINICAL TRIALS
In the past, most randomized clinical trials of glaucoma therapy relied on the reduction of IOP as the primary study endpoint. The studies that did not rely solely on IOP reduction, most often examined the progression of visual field loss (e.g. the Advanced Glaucoma Intervention Study, 5 and Collaborative Initial Glaucoma Treatment Study 6 ) and did not include an independent measure of optic disc structure as a primary study endpoint. More recently three randomized clinical trails (Ocular Hypertension Treatment Study (OHTS), 7 Early Manifest Glaucoma Study (EMGT), 8 and the European Glaucoma Prevention Study (EGPS) 9 have included assessment of the optic disc along with visual field testing as primary endpoints for open angle glaucoma. These well-designed studies provide important information on the temporal relationship between structural and functional change in early glaucoma (Tables 1 and 2 ).
The OHTS and EGPS evaluated whether ocular hypotensive treatment delayed or prevented the development of glaucoma in participants with ocular hypertension. The OHTS, a National Eye Institute multi-center randomized clinical trial of 1636 ocular hypertensive patients, found that topical ocular hypotensive medication was effective in delaying and/or preventing the onset of POAG. 10 In contrast to the OHTS, the EGPS a multi-center randomized, double-masked, placebo controlled study of 1,077 ocular hypertensives found that neither the degree of IOPlowering nor the rate of progression to POAG was statistically different between the dorzolamide treated and placebo groups. Although these studies came to different conclusions regarding the effect ocular hypertensive treatment on the development of glaucoma, both studies reported a substantial proportion of eyes with either structural or functional change as the first sign of glaucoma. Specifically, the OHTS 10 and EGPS 11 showed that, in many eyes, repeatable structural defects were the first sign of glaucoma (55% and 40% respectively), whereas, in some eyes, functional defects were the first sign of progressive change (35% and 60%, respectively). A very small proportion of eyes (10% in the OHTS and 0% in the EGPS) showed structural and functional change at the same time. It should be noted that the definition of the study endpoints of the OHTS and EGPS were similar (but not identical), 12 with both using masked independent assessment of stereophotography and repeatable visual field change confirmed by an endpoint committee (Table 1 ). In addition, both studies reported good reproducibility in the assessment of the stereophotographs. [13] [14] [15] The EMGT reported that in early glaucoma patients, treatment was effective in reducing glaucomatous progression. 16 EMGT compared the development of optic disk and visual field changes in 129 early glaucoma patients randomized to the treatment arm (treatment with betaxolol and argon laser trabeculoplasty) to 126 patients assigned to the observation arm. In contrast to OHTS and EGPS, EMGT used utilized flicker chronoscopy and side-by-side comparisons of non-stereoscopic fundus photographs for identifying optic disc change and the glaucoma change probability maps (based on visual field pattern deviation changes) for detecting functional change. Of the 136 eyes that progressed, the vast majority (86%) was detected by visual function only while only 1% had optic disc change. Another 13% of the progressing eyes were identified by both structural and functional change at the same time. The higher proportion of eyes with visual field as opposed to optic change in EMGT compared to OHTS and EGPS can be explained in part by the lack of stereophotography assessment of optic disc change as well as to differences in the study populations and stage of disease. For example, EMGT was a population-based study of Scandinavians with early glaucoma, with 23 (10%) participants with documented exfoliation at baseline. The EGPS cohort was drawn from several European countries and reported only 18 patients (1.7%) with pseudoexfoliation at baseline, while the OHTS cohort excluded eyes with pseudoexfoliation, 12 and by design included approximately 25% African Americans.
OBSERVATIONAL COHORT STUDIES
Early observational cohort studies highlighted the importance of structural evaluation in glaucoma management by providing evidence that RNFL and optic disc change based on photographic assessment can occur before detectable visual field change. [17] [18] [19] Other early studies suggested that progression was detectable earlier using short wavelength automated perimetry (SWAP) than SAP. [20] [21] [22] These early studies were small, often with some bias in patient selection that make it difficult to generalize the results to the general population of glaucoma patients and suspects. For example, Sommer et al, 17 reported that in 1344 eyes with elevated IOP over a 6-year period, up to 60% of eyes (depending on the grader) had RNFL defects (qualitative assessment with red-free photography) 6 years before the onset of Goldmann based visual field loss. The often cited 60% of eyes with RNFL defects preceding visual field damage was based on a very small sample of 6 out of 10 eyes. With respect to selective visual field loss, the early studies often required SAP but not SWAP testing to be normal at study entry, resulting in a biased comparison of the diagnostic accuracy of the two types of visual field tests; 20-22 SWAP damage could be detected at study entry before SAP, while a SAP defect at study entry resulted in exclusion from the study. Despite these methodological limitations, the overall conclusion is consistent from these studies; both structural and functional change can be the first sign of glaucomatous progression.
More recently, well-designed studies using imaging and selective functional tests have been initiated to evaluate whether new tests are better at identifying glaucomatous progression. These studies also provide information on the temporal relationship between structural and functional change. Because glaucoma is a slowly progressing disease, especially when treated, studies investigating change over time require extensive follow-up. Therefore, to date there are only a limited number of published studies that include both imaging instruments and standard or selective visual function tests to assess glaucomatous progression. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Since the HRT is the only optical imaging technology whose image acquisition technique has remained stable since its initial commercialization, most of the longitudinal imaging studies compare change in HRT optic disc topography to SAP. 24 30 reported that 31 (40%) of 77 glaucoma eyes showed progression only based on HRT Topographic Change Analysis (TCA), 22 (29%) eyes showed changes on both HRT TCA and SAP (defined using Statpac Glaucoma Change Probability Analysis), and only 3 (4%) showed change only on SAP. Table 3 summarizes the results of selected observational cohort studies. In general, regardless of the type of structural or functional test used, these studies suggest that the first sign of glaucomatous change can be either structural or functional. Differences between these studies can be explained at least in part by differences in the criteria used to define glaucomatous progression. For example, several studies have shown that various algorithms used in clinical trials for identifying glaucomatous visual field progression identify different proportions of patients with progressive visual field loss. 23, 38, 39 A number of well-designed studies explicitly assess the effect of applying different stringency criteria for defining structural and functional progression in the same study population. Artes and Chauhan 31 compared SAP, high pass resolution perimetry and HRT topographic change analysis in glaucoma patients utilizing three criteria of change (least conservative, intermediate and conservative) for each test. Regardless of the criteria, they found rather limited agreement between SAP, high pass resolution perimetry and HRT for detecting change after an average of 7 years of follow-up and concluded that these indicators of structural and functional change provide "largely independent measures of progression". Specifically, among the 60 patients classified as progressing using the least conservative criteria by at least one test, only 6 (10%) met the criteria for all 3 tests. Similarly, using the most conservative criteria, only 2 of the 27 (7%) progressing eyes showed progression on all 3 tests. Strouthidis et al. 25 compared rates of rim area and SAP sensitivity change over time in 198 ocular hypertensive patients and found that, depending on the stringency of the criteria, between 8% and 21% of eyes had documented rim area change, and another 15 to 20% had documented change in visual field sensitivity. Only 3 to 12% had both documented rim area and visual field sensitivity change. The authors conclude that "The results indicate that, in patients with ocular hypertension, monitoring of both VF and optic disc is necessary, as agreement between optic disc and VF progression is the exception rather than the rule." In summary, using a variety of diagnostic tests and definitions of progression from observational cohort studies provide evidence that in some eyes (13 to 42%), glaucomatous structural change is detected first, while in other eyes (4 to 42%) functional change is the first sign of glaucoma. [23] [24] [25] [26] [27] [28] 30, 31, 35, 37 Moreover, these studies consistently show that in fewer eyes (3 to 34%), structural and functional changes are detected at the same time.
DISCUSSION
There are many possible explanations for why in some eyes, structural change is detected first, whereas in others, functional change is detected first (See Hood and Kardon 29 for an excellent discussion of this issue). First, the ability to detect structural and functional damage depends on the instrument and parameters used to detect it. Since we cannot measure retinal ganglion cell function directly, we must rely on surrogates such as structural and functional testing. For example, visual function tests are designed to indirectly assess ganglion cell dysfunction. In some eyes, these psychophysical changes can be identified before cell death or before an anatomical structural change can be detected. It is also likely that in some eyes, structural changes can be detectable before visual sensitivity loss in areas of the visual field where redundancy of ganglion cells is high. Currently, there is no consensus on the best test or criteria for detecting glaucomatous change. 2 Moreover, the definition of progression in clinical studies and clinical practice is determined by balancing the magnitude of detectable change (signal) desired, with the variability of its detection (noise). If one tries to detect the earliest sign of change, it may be difficult to identify reproducibly and may lead to false positives; a larger change may be more reproducibly detected. Balancing these considerations to detect progression in an individual patient may be different from identifying small differences in the average course of disease in a group of patients in a clinical study. 2 Finally, as the reproducibility of tests varies by individual, type of test, and stage of disease, the test with the lowest variability (structural or functional) may reveal the first sign of glaucomatous change for a particular individual patient.
29,31
Which Technique to Use?
Techniques to monitor structural and functional change are improving. Based on the evidence from a limited number of studies available, there is no one structural or functional test or analysis technique that clearly outperforms the others in the detection of progression.
2,40,41 (See Anderson et al 2 for a discussion of test criteria important for the detection of progression). A recent American Academy of Ophthalmology Opthalmic Technology Assessment Report reviewed imaging instruments for detection of glaucoma and its progression and concluded that "Based on studies that have compared the various available technologies directly, there is no single imaging device that outperforms the others in distinguishing patients with glaucoma from controls. 40 Sakata et al 41 recently reviewed the evidence for selective perimetry in glaucoma management and concluded that "….visual dysfunction in eyes with early glaucoma varies significantly between individuals and no single technique is superior to the others in all patients."
Techniques with lower measurement variability will be more likely to detect repeatable change. Each technique has advantages and disadvantages, and it is important for the clinician to understand the strengths and limitations of the technique used in their clinic. [41] [42] [43] [44] Moreover, both structural and functional techniques should be used in conjunction with a careful clinical examination.
SUMMARY
Consistent evidence from clinical trials and observational cohort studies suggests that the first sign of glaucomatous change can be structural or functional. This is true in studies of ocular hypertensive patients and patients with early to moderate glaucoma using a variety of techniques and definitions of glaucomatous change. Based on current evidence, there is no one structural or functional technique that outperforms the others in detecting glaucomatous progression. Therefore, monitoring both structural and functional change in conjunction with a thorough clinical examination is essential for proper management of glaucoma patients.
